Antiviral drug resistance: mechanisms and clinical implications.

Antiviral drug resistance is an increasing concern in immunocompromised patient populations, where ongoing viral replication and prolonged drug exposure lead to the selection of resistant strains. Rapid diagnosis of resistance can be made by associating characteristic viral mutations with resistance to various drugs as determined by phenotypic assays. Management of drug resistance includes optimization of host factors and drug delivery, selection of alternative therapies based on knowledge of mechanisms of resistance, and the development of new antivirals. This article discusses drug resistance in herpesviruses and hepatitis B.

[1]  K. Hostetler,et al.  Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. , 2008, Antiviral research.

[2]  D. Knight,et al.  Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. , 1999, Intervirology.

[3]  M. Kalaycio,et al.  Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection , 2004, Bone Marrow Transplantation.

[4]  J. Markmann,et al.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin , 1998, Hepatology.

[5]  A. Webster,et al.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. , 2006, The Cochrane database of systematic reviews.

[6]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[7]  T. Klingebiel,et al.  Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. , 1999, The Journal of infectious diseases.

[8]  C. Perry,et al.  Valaciclovir , 2000, Drugs.

[9]  M. Levin,et al.  Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. , 2003, The Journal of infectious diseases.

[10]  R. Razonable,et al.  Emergence of drug‐resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes , 2007, Clinical transplantation.

[11]  S. Chou,et al.  Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. , 2007, The Journal of infectious diseases.

[12]  David Sutton,et al.  Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy , 2003, Clinical Microbiology Reviews.

[13]  S. Chou,et al.  Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens , 2007, Antimicrobial Agents and Chemotherapy.

[14]  F. Zoulim.  In vitro models for studying hepatitis B virus drug resistance. , 2006, Seminars in liver disease.

[15]  Huiling Yang,et al.  In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. , 2004, Antiviral research.

[16]  S. Chou,et al.  Multidrug Resistance Conferred by Novel DNA Polymerase Mutations in Human Cytomegalovirus Isolates , 2006, Antimicrobial Agents and Chemotherapy.

[17]  S. Lee,et al.  A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. , 1997, The Journal of infectious diseases.

[18]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[19]  I. Bassett,et al.  Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. , 2007, Blood.

[20]  H. Einsele,et al.  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2001, Blood.

[21]  S. Chou,et al.  Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. , 2002, The Journal of infectious diseases.

[22]  G. Darby,et al.  Survey of Resistance of Herpes Simplex Virus to Acyclovir in Northwest England , 1998, Antimicrobial Agents and Chemotherapy.

[23]  T. Efferth,et al.  The antiviral activities of artemisinin and artesunate. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  O. Laskin,et al.  ISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY , 1982, The Lancet.

[25]  S. Chou,et al.  A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. , 2000, The Journal of infectious diseases.

[26]  G. Andrei,et al.  Novel agents for the therapy of varicella-zoster virus infections , 2000, Expert opinion on investigational drugs.

[27]  L. Hilliard,et al.  ACYCLOVIR-RESISTANT CHRONIC VERRUCOUS VACCINE STRAIN VARICELLA IN A PATIENT WITH NEUROBLASTOMA , 2008, The Pediatric infectious disease journal.

[28]  D. Jabs,et al.  Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. , 1998, The Journal of infectious diseases.

[29]  P. Chiusolo,et al.  Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. , 2004, Haematologica.

[30]  H. Frangoul,et al.  Acyclovir‐resistant herpes simplex virus pneumonia post‐unrelated stem cell transplantation: A word of caution , 2007, Pediatric transplantation.

[31]  S. Chou,et al.  Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  G. Bou,et al.  Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  D. Miklos,et al.  Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  E. Keeffe,et al.  Chronic hepatitis B: early viral suppression and long‐term outcomes of therapy with oral nucleos(t)ides , 2009, Journal of viral hepatitis.

[35]  D. Pillay,et al.  Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. , 2000, The Journal of infectious diseases.

[36]  J. Huraux,et al.  Point mutations in the varicella‐zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype , 1999, Journal of medical virology.

[37]  H. Balfour,et al.  Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. , 1998, The Journal of infectious diseases.

[38]  J. Cherrington,et al.  Clinical uses of cidofovir , 1997, Reviews in medical virology.

[39]  I. Serra,et al.  Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. , 2009, Antiviral research.

[40]  H. Balfour,et al.  Ganciclovir‐resistant cytomegalovirus encephalitis in a bone marrow transplant recipient , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[41]  H. Balfour,et al.  Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. , 1989, The New England journal of medicine.

[42]  M. Manns,et al.  Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.

[43]  F. Chan,et al.  Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. , 2005, Journal of hepatology.

[44]  W. Drew.  Is combination antiviral therapy for CMV superior to monotherapy? , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[45]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[46]  A. Limaye,et al.  Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  H. Esperou,et al.  Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Vij,et al.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Blood.

[50]  S. Chou,et al.  Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene , 2005, Antimicrobial Agents and Chemotherapy.

[51]  E. De Clercq,et al.  In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? , 2004, Antiviral research.

[52]  K. Tyler,et al.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[54]  S. Chou,et al.  Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir , 2004, Journal of Virology.

[55]  C. Wilfert,et al.  Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. , 1982, The Journal of infectious diseases.

[56]  R. Starling,et al.  A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus , 2007, Transplantation.

[57]  D. Jabs,et al.  Incidence of Foscarnet Resistance and Cidofovir Resistance in Patients Treated for Cytomegalovirus Retinitis , 1998, Antimicrobial Agents and Chemotherapy.

[58]  E. Kern,et al.  Oral Activity of a Methylenecyclopropane Analog, Cyclopropavir, in Animal Models for Cytomegalovirus Infections , 2004, Antimicrobial Agents and Chemotherapy.

[59]  E. Schiff,et al.  Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  R. Stranska,et al.  Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[61]  H. Zimmermann,et al.  Antiviral strategies to combat cytomegalovirus infections in transplant recipients. , 2008, Current opinion in pharmacology.

[62]  T. Efferth,et al.  The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. , 2006, Antiviral research.

[63]  E. Benedetti,et al.  Use of high‐dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[64]  A. Wagstaff,et al.  Foscarnet , 2012, Drugs.

[65]  Aijaz Ahmed,et al.  Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. , 2009, The Journal of infectious diseases.

[66]  S. Chou,et al.  Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. , 1998, The Journal of infectious diseases.

[67]  S. Chou,et al.  Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[68]  M. Imamura,et al.  Successful treatment of an entecavir‐resistant hepatitis B virus variant , 2007, Journal of medical virology.

[69]  P. Schaffer,et al.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[70]  W. Mason,et al.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.

[71]  Y. Liu,et al.  Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.

[72]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[73]  A. Limaye.  Ganciclovir-resistant cytomegalovirus in organ transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  N. Lurain,et al.  Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[75]  H. Klenk,et al.  A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene Products , 2001, Journal of Virology.

[76]  A. Griffiths,et al.  Translational Compensation of a Frameshift Mutation Affecting Herpes Simplex Virus Thymidine Kinase Is Sufficient To Permit Reactivation from Latency , 2003, Journal of Virology.

[77]  D. Wolf,et al.  Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[79]  D. Jabs,et al.  Cytomegalovirus Retinitis and Viral Resistance: Ganciclovir Resistance , 1998 .

[80]  T. Berger,et al.  Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. , 1991, Annals of internal medicine.

[81]  K. Kowdley,et al.  Hepatitis B and liver transplantation. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  S. Litwin,et al.  The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[83]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[84]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[85]  A. Griffiths,et al.  Low-Level Expression and Reversion both Contribute to Reactivation of Herpes Simplex Virus Drug-Resistant Mutants with Mutations on Homopolymeric Sequences in Thymidine Kinase , 2006, Journal of Virology.

[86]  J. Huraux,et al.  Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. , 1998, The Journal of infectious diseases.

[87]  G. Elion,et al.  In vitro susceptibility of varicella-zoster virus to acyclovir , 1980, Antimicrobial Agents and Chemotherapy.

[88]  Y. Liaw,et al.  Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. , 2005, Journal of hepatology.

[89]  P. Fayers,et al.  DRIED-MILK INFANT FEEDS , 1976, The Lancet.

[90]  C. Crumpacker.  Drug therapy : Ganciclovir , 1996 .

[91]  S. Chou,et al.  Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant , 2007, Journal of Virology.

[92]  Michael D. Miller,et al.  Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus , 2006, Antimicrobial Agents and Chemotherapy.

[93]  E. Clercq.  The antiviral spectrum of (E)-5-(2-bromovinyl)-2 ′-deoxyuridine , 1984 .

[94]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  D. Raoult,et al.  Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up , 2004, Journal of Clinical Microbiology.

[96]  D. Malvy,et al.  A retrospective, case-control study of acyclovir resistance in herpes simplex virus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  C. Katlama,et al.  Foscarnet nephrotoxicity: mechanism, incidence and prevention. , 1989, American journal of nephrology.

[98]  H. Balfour,et al.  Herpes Simplex Virus Resistant to Acyclovir: A Study in a Tertiary Care Center , 1990 .

[99]  W. Haefeli,et al.  Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. , 1993, The American journal of medicine.

[100]  N. Sadick,et al.  Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. , 1988, JAMA.

[101]  S. Chou,et al.  Maribavir Antagonizes the Antiviral Action of Ganciclovir on Human Cytomegalovirus , 2006, Antimicrobial Agents and Chemotherapy.

[102]  A. Lok,et al.  How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[103]  H. Agut,et al.  Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[105]  E. Kern,et al.  In Vitro Activity and Mechanism of Action of Methylenecyclopropane Analogs of Nucleosides against Herpesvirus Replication , 2005, Antimicrobial Agents and Chemotherapy.

[106]  M. Yuen,et al.  Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients , 2004, Hepatology.

[107]  F. Negro,et al.  Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. , 2001, Journal of hepatology.

[108]  C. Crumpacker,et al.  A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. , 1991, The New England journal of medicine.

[109]  S. Chou,et al.  Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. , 2003, The Journal of infectious diseases.

[110]  D. Coen,et al.  A Recombinant Human Cytomegalovirus with a Large Deletion in UL97 Has a Severe Replication Deficiency , 1999, Journal of Virology.

[111]  P. Schirmacher,et al.  Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[112]  M. Aymard,et al.  Occurrence and characterization of acyclovir‐resistant herpes simplex virus isolates: Report on a two—year sensitivity screening survey , 1992, Journal of medical virology.

[113]  E. Shpall,et al.  Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug‐resistant herpes simplex virus infection , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[114]  K. Hostetler,et al.  Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir , 2004, Antimicrobial Agents and Chemotherapy.

[115]  R. Fontana,et al.  Management of drug-resistant chronic hepatitis B. , 2006, Clinics in liver disease.

[116]  S. Chou,et al.  How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients , 2005, Journal of Clinical Microbiology.

[117]  S. Seo,et al.  Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[119]  A. Weinberg,et al.  Treatment of multidrug‐resistant cytomegalovirus retinitis with systemically administered leflunomide , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[120]  M. Battiwalla,et al.  Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[121]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[122]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[123]  D. Knight,et al.  Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent Leflunomide , 2000, Intervirology.

[124]  F. Zoulim,et al.  In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. , 2009, Gastroenterology.

[125]  P. Angus,et al.  Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. , 2007, Gastroenterology.

[126]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[127]  G. Elion.  Acyclovir: Discovery, mechanism of action, and selectivity , 1993, Journal of medical virology.

[128]  Guy Boivin,et al.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[129]  A. Solinger,et al.  Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. , 1990, AIDS.

[130]  H. Balfour,et al.  Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. , 1994, The Journal of infectious diseases.

[131]  M. Jacobson,et al.  Acyclovir‐resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS) , 1990, Annals of internal medicine.

[132]  D. Wyles,et al.  Development of herpes simplex virus disease in patients who are receiving cidofovir. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[133]  M. Aymard,et al.  Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. , 2000, The Journal of infectious diseases.

[134]  M. Saijo,et al.  Rapid Phenotypic Characterization Method for Herpes Simplex Virus and Varicella-Zoster Virus Thymidine Kinases To Screen for Acyclovir-Resistant Viral Infection , 2000, Journal of Clinical Microbiology.

[135]  G. Boivin,et al.  Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids , 2003, Journal of Virology.

[136]  F. Zoulim,et al.  Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. , 2008, Journal of hepatology.

[137]  C. K. Chu,et al.  Understanding the molecular basis of HBV drug resistance by molecular modeling. , 2008, Antiviral research.

[138]  E. Mylonakis,et al.  Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[139]  Ronald E. Rose,et al.  Inhibition of Hepatitis B Virus Polymerase by Entecavir , 2007, Journal of Virology.

[140]  F. Zoulim,et al.  Antiviral therapy of chronic hepatitis B: prevention of drug resistance. , 2007, Clinics in liver disease.

[141]  H. Schaeffer,et al.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[142]  P. Ljungman,et al.  Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. , 1990, The Journal of infectious diseases.

[143]  H. Lee,et al.  Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.

[144]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[145]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[146]  N. Warner,et al.  Major Causes of Antiviral drug Resistance and Implications for Treatment of Hepatitis B virus Monoinfection and Coinfection with HIV , 2006, Antiviral therapy.

[147]  H. Einsele,et al.  European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.

[148]  P. Angus,et al.  A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis , 2008, Hepatology.

[149]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. , 1998, Hepatology.

[150]  W. Freeman,et al.  High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. , 1997, The Journal of infectious diseases.

[151]  A. Neumann,et al.  Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[152]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[153]  S. Chou,et al.  Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[154]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[155]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[156]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[157]  S. Kung,et al.  A cell line that secretes inducibly a reporter protein for monitoring herpes simplex virus infection and drug susceptibility , 2002, Journal of medical virology.

[158]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[159]  D. Coen.  Acyclovir-resistant, pathogenic herpesviruses. , 1994, Trends in microbiology.

[160]  C. Crumpacker,et al.  A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates , 2000, Antimicrobial Agents and Chemotherapy.

[161]  S. Gruber,et al.  Sirolimus exposure during the early post‐transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients , 2007, Clinical transplantation.

[162]  G. Ewald,et al.  Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1‐Year Report , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[163]  H. Einsele,et al.  Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. , 2003 .

[164]  C. Katlama,et al.  Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[165]  M. Froeyen,et al.  DNA Polymerase Mutations in Drug-Resistant Herpes Simplex Virus Mutants Determine In Vivo Neurovirulence and Drug-Enzyme Interactions , 2007, Antiviral therapy.

[166]  U. Spengler,et al.  Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[167]  A. Zaas,et al.  A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[168]  J. Molina,et al.  Topical imiquimod for recurrent acyclovir-resistant HSV infection. , 2006, The American journal of medicine.

[169]  A. Berger,et al.  Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? , 2007, Gut.

[170]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[171]  M. Yuen,et al.  Prevention and management of drug resistance for antihepatitis B treatment. , 2009, The Lancet. Infectious diseases.

[172]  E. Trulock,et al.  The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. , 1999, Transplantation.

[173]  G. Painter,et al.  Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. , 2003, Antiviral research.

[174]  D. Faulds,et al.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.

[175]  B. Lina,et al.  Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis Study , 2005, Antimicrobial Agents and Chemotherapy.

[176]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[177]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[178]  A. Limaye,et al.  Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.

[179]  T. Klingebiel,et al.  Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery , 2002, Bone Marrow Transplantation.

[180]  S. Kako,et al.  Case Report: Persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes , 2008, Journal of medical virology.

[181]  A. Humar,et al.  Clinical impact of ganciclovir‐resistant cytomegalovirus infections in solid organ transplant patients , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[182]  S. Chou,et al.  Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[183]  M. Kurokawa,et al.  Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. , 2001, The Journal of general virology.

[184]  M. Blum,et al.  Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. , 2008, Transplantation proceedings.

[185]  M. Yuen,et al.  Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population , 2007, Antiviral therapy.

[186]  J. Stoner,et al.  Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy , 2009, PloS one.

[187]  J. Bremer,et al.  Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. , 2002, The Journal of infectious diseases.

[188]  M. Goldman,et al.  Clinical characteristics of 13 solid organ transplant recipients with ganciclovir‐resistant cytomegalovirus infection , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[189]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[190]  E. Thervet,et al.  Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[191]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[192]  B. Lina,et al.  Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir , 1999, Antimicrobial Agents and Chemotherapy.

[193]  Y. Bertrand,et al.  Acyclovir‐resistant varicella infection with atypical lesions in a non‐HIV leukemic infant , 2000, Acta paediatrica.

[194]  G. Raghu,et al.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. , 2002, The Journal of infectious diseases.

[195]  K. Tanikawa,et al.  Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B , 2009, Hepatology international.

[196]  T. Heffron,et al.  Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual‐strain cytomegalovirus coinfection , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[197]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[198]  D. Thouvenot,et al.  Herpes simplex virus resistance to antiviral drugs. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[199]  H. Balfour,et al.  Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. , 1998, The Journal of infectious diseases.

[200]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.